Cambridge Healthtech Institute’s 4th Annual
Translational Strategies, Small Molecule Targets and Immune Profiling
June 2-4, 2020
Immuno-oncology research and the subsequent development of immunotherapies continue to rapidly advance the fight against cancer. First-generation agents that achieved remarkable clinical success have inspired researchers to pursue a variety of new treatment
modalities and created a robust development landscape centered on combinations strategies. The 4th Annual Immuno-Oncology Advances conference, part of World Pharma Week, will feature three key areas that include preclinical and translational
strategies, small molecule targets in immuno-oncology, and immune profiling and monitoring.
Coverage will include, but is not limited to:
Translational Strategies in Immuno-Oncology
- Reverse translational studies to guide cancer combination strategies
- Leveraging the best of industry and academia to create new cancer medicines
- Leveraging artificial intelligence in preclinical and translational oncology
- Combination strategies
Immuno-Oncology Small Molecule Targets
- Modulators of the innate immune system (e.g.; STING)
- Inhibitors of immune cell metabolism
- Nuclear receptor targets (e.g.; ROR)
Immune Profiling and Monitoring
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is November 22, 2019.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Marina Filshtinsnky, MD
Executive Director, Conferences
Cambridge Healthtech Institute
For partnering and sponsorship information, please contact:
Manager, Business Development
Joseph Vacca, M.S.
Director, Business Development